@article{a689589a2c5a42029c356fbb29a7f1c7,
title = "Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases",
abstract = "Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.[GRAPHICS].",
keywords = "Amyloidosis, Cardiac amyloidosis, Diagnosis, Treatment, AL, TTR, Transthyretin, TRANSTHYRETIN AMYLOIDOSIS, HEREDITARY, CARDIOMYOPATHY, MANAGEMENT, NOMENCLATURE, PREDICTORS",
author = "Pablo Garcia-Pavia and Claudio Rapezzi and Yehuda Adler and Michael Arad and Cristina Basso and Antonio Brucato and Ivana Burazor and Caforio, {Alida L. P.} and Thibaud Damy and Urs Eriksson and Marianna Fontana and Gillmore, {Julian D.} and Esther Gonzalez-Lopez and Martha Grogan and Stephane Heymans and Massimo Imazio and Ingrid Kindermann and Arnt Kristen and Maurer, {Mathew S.} and Giampaolo Merlini and Antonis Pantazis and Sabine Pankuweit and Rigopoulos, {Angelos G.} and Ales Linhart",
note = "Funding Information: P.G.-P. reports grant support from Instituto de Salud Carlos III (PI20/01379). M.F. is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/21/33447). E.G.-L. reports grant support from Instituto de Salud Carlos III (PI18/0765). M.S.M. reports grant support from National Institutes of Health [R01HL139671-01], [R21AG058348], and [K24AG036778]. Funding Information: Conflict of interest: M.A. reports receiving an Advisory board fee and a Research Grant from Pfizer and from Sanofi Genzyme. U.E. reports consulting fees and grant support from Pfizer and Sanofi. Institutional grants from Pfizer. M.F. reports consulting fees from Pfizer, Akcea, Ionis, Alnylam, Alexion, Sanofi, and research grant from Pfizer. P.G.P. reports speaking fees from Pfizer, Eidos, Alnylam, and Akcea. Consulting fees from Pfizer, Eidos, Neuroinmmune, Alnylam, Prothena, and Akcea. Research support to his institution from Pfizer, Eidos, and Alnylam. J.D.G. reports consulting and speaking fees from Pfizer, Akcea, Alnylam, and Eidos. E.G.-L. reports speaking fees from Pfizer and Alnylam. Consulting fees from Pfizer and Proclara. Research support to her institution from Pfizer, Eidos, and Alnylam. M.G. reports grant/clinical trial support from Alnylam, Eidos, Prothena, and Pfizer. I.K. reports speaking fees from Akcea Therapeutics Germany and Pfizer and consulting fees from Akcea Therapeutics Germany. A.V.K. reports consulting fees from Pfizer, Akcea, Alnylam, and Neurimmune as well as speaking fees from Pfizer, Akcea, and Alnylam. A.L. reports speaking fees from Pfizer. Consulting fees from Pfizer and Alnylam. M.S.M. reports consulting income from Pfizer, GSK, EIdos, Prothena, Akcea, and Alnylam, and institution received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. C.R. reports speaking fees from Pfizer, Alnylam, and Akcea. Consulting fees from Pfizer, Alnylam, Prothena, and Akcea. Institutional Research Grants from Pfizer. A.G.R. reports honoraria for presentations from Astra-Zeneca. Other authors declare no conflict of interest. Publisher Copyright: {\textcopyright} The Author(s), 2021.",
year = "2021",
month = apr,
day = "21",
doi = "10.1093/eurheartj/ehab072",
language = "English",
volume = "42",
pages = "1554--1568",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "16",
}